FDA Approves Treatment Option for Congenital Factor XIII A-Subunit Deficiency
Novo Nordisk is pleased to announce that the US Food and Drug Administration (FDA) has approved TRETTEN® (Coagulation Factor XIII A-Subunit [Recombinant]) for the routine prophylaxis of bleeding in people with congenital factor XIII (FXIII) A-subunit deficiency, one of the rarest inherited bleeding disorders. TRETTEN® is the only recombinant treatment for the disease. Patients with […]
Get Healthy in the New Year!
Vegetables and fruits are high in antioxidants and fiber, and low in calories.
English 
Español de Puerto Rico